Revance to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Revance Therapeutics, Inc. (Nasdaq: RVNC) announced that CEO Mark Foley will participate in a fireside chat during the Piper Sandler 32nd Annual Virtual Healthcare Conference, available online starting December 1, 2020. The conference runs from December 1-3, 2020. Revance specializes in innovative aesthetic and therapeutic products, including DaxibotulinumtoxinA for Injection, which targets facial wrinkles and spasticity disorders. The company aims for U.S. regulatory approval in 2020 and has a portfolio of services, including the RHA® Collection of dermal fillers.
- None.
- None.
NEWARK, Calif.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company’s President and Chief Executive Officer, Mark Foley, will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference.
The fireside chat will be available online beginning December 1 in the investor relations section of the company’s website at www.revance.com. The virtual conference will be held from December 1-3, 2020.
About Revance Therapeutics, Inc.
Revance Therapeutics, Inc. is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain human or animal-based components. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020. Revance is also evaluating DaxibotulinumtoxinA for Injection in the full upper face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications - cervical dystonia and adult upper limb spasticity. To accompany DaxibotulinumtoxinA for Injection, Revance has built a unique portfolio of premium products and services for U.S. aesthetics practices, including the RHA® Collection of dermal fillers in the U.S., the first and only range of FDA-approved fillers for correction of dynamic facial wrinkles and folds, and the HintMD fintech platform, which includes integrated smart payment, subscription and loyalty digital services. Revance has also partnered with Viatris (formerly Mylan N.V.) to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace. Revance is dedicated to making a difference by transforming patient experiences. For more information or to join our team visit us at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
RHA resilient hyaluronic acid® and RHA® are trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.
